Caribou Biosciences falls as analysts downgrade on strategic alternatives exploration
FROM THE WIRE · SEEKINGALPHA.COM
Shares of Caribou Biosciences (CRBU [https://seekingalpha.com/symbol/CRBU]) reached an all-time low on Wednesday after the cell therapy developer announced plans to explore strategic alternatives, prompting RBC Capital Markets and Leerink Partners to downgrade the biotech.…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bearishCaribou announces workforce cuts and CAR-T program halts, prompting analyst downgrades and stock hitting all-time lows.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Caribou announced workforce and cost reductions plus halt of allogeneic CAR-T programs vispa-cel and CB-011.
- 02The move reflects significant capital requirements to fund planned Phase 3 ANTLER-3 trial for lead asset.
- 03RBC Capital Markets and Leerink Partners downgraded the stock following strategic alternatives announcement.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets